Leary, A., Johnston, S. R. D. (2007) Small molecule signal transduction inhibitors for the treatment of solid tumors. CANCER INVESTIGATION, 25 (5). pp. 347-365. ISSN 0735-7907

Full text not available from this repository.

Abstract

A greater understanding of the pathogenesis of malignancy has led to the development of novel therapies designed to target aberrant molecular pathways that characterize and distinguish cancer cells from normal tissue. Small molecules are being designed to interfere with specific steps along the deregulated signaling cascade from the cytoplasmic membrane to the nucleus. Viable targets include growth factor receptors and their downstream second messengers, modulators of the cell cycle or apoptosis, regulators of protein trafficking and degradation, and transcription regulators. This review will discuss the small molecule signal transduction inhibitors in various stages of development and address the strategic issues relating to clinical trial design with these novel targeted agents.

Item Type:	Review Article
Authors (ICR Faculty only):	Johnston, Stephen
All Authors:	Leary, A., Johnston, S. R. D.
Uncontrolled Keywords:	targeted therapy; tyrosine kinase inhibitors; biomarkers; signaling; cancer GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; PHASE-I TRIAL; FARNESYL TRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; PACLITAXEL-MEDIATED CYTOTOXICITY; GASTROINTESTINAL STROMAL TUMORS; SUBEROYLANILIDE HYDROXAMIC ACID
Research teams:	Clinical Units > Breast Unit
Depositing User:	Users 6 not found.
Date Deposited:	20 Jun 2008 09:04
Last Modified:	01 Oct 2009 14:06
URI:	http://publications.icr.ac.uk/id/eprint/5145

Actions (login required)

View Item